Relora (Magnolia officinalis, Phellodendron amurense)

Relora is a standardized extract combining Magnolia officinalis bark and Phellodendron amurense bark, containing honokiol and berberine as key bioactive compounds. These compounds modulate the HPA axis and GABA receptors to reduce cortisol production and promote relaxation without sedation.

Origin & History

Relora is a proprietary blend of bark extracts from Magnolia officinalis and Phellodendron amurense, two trees native to East Asia. It is produced through solvent extraction using water or ethanol, involving reflux for 8-48 hours, filtration, and concentration, with standardization targeting ≥2% honokiol by weight.

Historical & Cultural Context

Magnolia officinalis bark (Hou Po) has been used in Traditional Chinese Medicine for over 2000 years to treat anxiety and digestive issues through qi regulation. Phellodendron amurense bark (Huang Bai) has been a TCM staple for 1000+ years for heat-clearing and treating infections, combining traditional herbal pairings for modern stress applications.

Health Benefits

• Reduces stress and anxiety scores by 18-20% based on Hamilton Anxiety Rating Scale (moderate evidence from RCT, n=56)
• Lowers salivary cortisol by 18% and serum cortisol by 15% versus placebo (moderate evidence from RCT, n=56)
• Improves sleep quality and mood parameters (moderate evidence from RCT, n=56)
• May reduce late-night eating and support modest weight control (preliminary evidence from small RCT, n=50)
• Modulates stress response through GABA enhancement and glutamate inhibition (mechanistic studies)

How It Works

Relora's primary compounds honokiol and magnolol act as positive allosteric modulators of GABAA receptors, enhancing inhibitory neurotransmission. These compounds also inhibit cortisol synthesis by downregulating HPA axis activity at the hypothalamic and adrenal levels. Berberine from Phellodendron contributes additional anxiolytic effects through serotonin and dopamine pathway modulation.

Scientific Research

A randomized, placebo-controlled trial (n=56, PMID: 18426577) found Relora (750 mg/day for 6 weeks) significantly reduced stress scores, cortisol levels, and improved mood. Another RCT (n=50) showed modest benefits for weight control and eating behaviors at 750-1125 mg/day, though evidence remains limited to small trials without meta-analyses.

Clinical Summary

A randomized controlled trial (n=56) demonstrated that Relora 250mg twice daily reduced Hamilton Anxiety Rating Scale scores by 18-20% compared to placebo over 4 weeks. The same study showed significant cortisol reductions of 18% in salivary measurements and 15% in serum levels. Additional studies support improvements in sleep quality and mood parameters, though the evidence base remains moderate with limited long-term data. Most clinical trials have been small-scale with follow-up periods under 8 weeks.

Nutritional Profile

Relora is a proprietary blend of two plant bark extracts — Magnolia officinalis and Phellodendron amurense — standardized for specific bioactive compounds rather than traditional macronutrients. Typical commercial dose is 250–500 mg per serving. Key bioactive compounds include: Honokiol (Magnolia officinalis bark) at approximately 1–5% concentration by weight in standardized extracts, exhibiting anxiolytic and GABAergic activity; Magnolol (Magnolia officinalis bark) at approximately 1–5% concentration, contributing anti-anxiety and cortisol-modulating effects — honokiol and magnolol together typically comprise 2–10% of standardized Magnolia extract. Berberine (Phellodendron amurense bark) present at low concentrations in Relora formulation (~0.1–1%), lower than isolated berberine supplements; Phellodendrine and Jatrorrhizine are additional isoquinoline alkaloids from Phellodendron contributing to adrenal modulation. Macronutrient content is negligible — essentially 0g protein, 0g fat, 0g carbohydrates per standard dose. No meaningful vitamin or mineral content. Fiber content is trace/negligible. Bioavailability notes: Honokiol demonstrates good oral bioavailability with lipophilic characteristics, enhanced by fat co-ingestion; peak plasma levels reached within 1–2 hours. Berberine in this formulation has limited bioavailability (~5%) due to P-glycoprotein efflux, though this is less clinically relevant given the low concentrations present in Relora specifically. The patented extraction process is designed to retain the cortisol-modulating synergy between both plant components.

Preparation & Dosage

Clinically studied doses: 250 mg three times daily (750 mg total/day) for stress and anxiety management, or 750-1125 mg/day for weight control support. All studies used capsules of the branded extract blend. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

L-Theanine, Ashwagandha, Rhodiola, Alpha-Lactalbumin, GABA

Safety & Interactions

Relora is generally well-tolerated with mild side effects including drowsiness, headache, and occasional digestive upset reported in less than 10% of users. The berberine component may interact with blood glucose medications and CYP3A4 substrates, requiring monitoring in diabetic patients. Pregnancy and breastfeeding safety has not been established, so use should be avoided during these periods. Potential additive effects may occur with other CNS depressants including benzodiazepines and sleep medications.